DEPARTMENT OF PACEMAKER AND ELECTROPHYSIOLOGY, SHAHEED RAJAIE CARDIOVASCULAR MEDICAL CENTER, MELLAT PARK, VALI-ASR AVENUE, TEHRAN, IRAN
One of the most important challenges in today's practice of cardiology is prevention of sudden cardiac death (SCD) in high risk patients with coronary heart disease (CAD). Hemodynamically tolerated sustained ventricular tachycardia (HTVT) comprises up to 30% of all cases of monomorphic ventricular tachycardia (MMVT) in patients with CAD. While there is a consensus on treatment of hemodynamically-unstable sustained VT in patients with CAD, some controversies regarding the proper treatment of HTVT exist. We re-examined existing clinical evidence, controversies and current guidelines on the treatment of HTVT in patients with CAD and demonstrated that compared to implantable cardioverter-defibrillators, amiodarone is not an acceptable therapeutic option in patients with ischemic heart disease who suffer from HTVT.